Mylan N.V. (MYL) Misses Q2 EPS by 15c, Guidance Misses
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Mylan N.V. (MYL) Misses Q2 EPS by 15c, Guidance Misses
August 8, 2018 11:34 AM EDT
Deutsche Bank analyst Gregg Gilbert said clients should buy Mylan (NASDAQ: MYL) with shoe dropped and options being explored.
Gilbert commented, "In a not-so-surprising development, MYLs 2Q results came in light and management lowered its 2018 outlook, primarily based on the re-basing of the US healthcare environment. A key headwind for MYL as it relates to investor... More
August 8, 2018 8:33 AM EDT
Global pharmaceutical company Mylan N.V.'s (NASDAQ: MYL) board of directors today released the following statement:
Over the past decade, Mylan's Board of Directors and management team have turned Mylan into a leading global platform with a highly-diversified portfolio of products across broad therapeutic areas and geographies. Our long-term strategy and management's continued execution have consistently served the best interests of all of our stakeholders.
Our international... More
